Drug Profile
Research programme: human papillomavirus vaccine - Crucell/Ortho-McNeil-Janssen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Crucell; Ortho-McNeil-Janssen Pharmaceuticals
- Developer Crucell; Johnson & Johnson Innovative Medicine
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Human-papillomavirus-infections in Netherlands
- 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
- 09 Nov 2010 Early research in Human papillomavirus infections in Netherlands (unspecified route)